Sponsor intelligence · OTHER
Clinical trials sponsored by
Sun Yat-Sen University.
Real, source-linked trial activity for Sun Yat-Sen University: 10 tracked trials, by phase and status, newest first. New trials = pipeline expansion = CRO, site, and reagent demand.
✔ Verified against the public NIH RePORTER & ClinicalTrials.gov records as of Aug 5, 2026. Source-linked, daily-refreshed.
PHASE2 6PHASE3 2N/A 1NA 1
Newest Sun Yat-Sen University trials
| Posted | Trial | Phase | Status | |
|---|---|---|---|---|
| 2d ago | Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2 | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 10d ago | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 10d ago | FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC | Ph 3 | NOT_YET_RECRUITING | ↗ |
| 17d ago | Efficacy and Safety of Tunlametinib Combination Therapy in the Treatme | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 21d ago | An Umbrella-designed Prospective Multicenter Randomized Open-label Sup | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 22d ago | Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-P | Ph 3 | RECRUITING | ↗ |
| 23d ago | Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) i | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 38d ago | Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB | N/A | NOT_YET_RECRUITING | ↗ |
| 50d ago | Rituximab Maintenance Versus Observation After R2 Induction in Previou | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 51d ago | Study on the Effects and Mechanisms of Probiotic Supplementation in Am | NA | NOT_YET_RECRUITING | ↗ |
Get this lane pushed to you the day a new grant or trial lands
Free email digest + a daily new-funding feed (JSON / MCP / webhook) of newly-awarded NIH grants and newly-registered clinical trials for Sun Yat-Sen University (trial sponsor). Watch institutions, PIs, sponsors, and topics. Newly-funded labs = new buyers, today.